Skip to main content
. Author manuscript; available in PMC: 2024 Jun 7.
Published in final edited form as: Neuron. 2023 Apr 5;111(11):1795–1811.e7. doi: 10.1016/j.neuron.2023.03.014

Figure 3. Oxytocin in the PL-PFC reduces chronic inflammatory pain.

Figure 3.

(A) Complete Freund’s adjuvant (CFA) or saline injection to rat’s hind paw.

(B) CFA decreased withdrawal threshold (****p < 0.0001, two-way ANOVA with repeated measures and Sidak’s multiple comparisons test; n = 6 animals).

(C) Intracranial OT, compared SAL, increased the withdrawal threshold in CFA-treated rats (****p < 0.0001, unpaired t test; n = 6 animals).

(D) Conditioned place preference (CPP) assay on tonic pain in CFA rats. Rats had SAL delivered intracranially in one chamber and OT delivered in the opposite chamber.

(E) CFA-treated rats demonstrated a preference for the chamber associated with OT (**p < 0.01, n = 8 animals).

(F) Control rats that received subcutaneous saline injections to paw demonstrated no preference for OT treatment (p = 0.8976, n = 8 animals).

(G) CFA-treated rats exhibited a preference for the chamber associated with OT (*p < 0.05, unpaired t test; n = 8 CFA and saline animals).

Data are represented as mean ± S.E.M.